PMID- 18397958
OWN - NLM
STAT- MEDLINE
DCOM- 20080626
LR  - 20171116
IS  - 1462-0332 (Electronic)
IS  - 1462-0324 (Linking)
VI  - 47
IP  - 6
DP  - 2008 Jun
TI  - Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely 
      correlating with disease activity.
PG  - 804-8
LID - 10.1093/rheumatology/ken033 [doi]
AB  - OBJECTIVE: Churg-Strauss Syndrome (CSS) is characterized by excessive eosinophil 
      accumulation in peripheral blood and affected tissues with development of 
      granulomatous vasculitic organ damage. The contribution of eosinophil-chemotactic 
      cytokines (eotaxin family) to eosinophilia and disease activity in CSS is 
      unknown. Thus, we compared serum levels of the eotaxin family members in CSS 
      patients with healthy and disease controls. METHODS: Forty patients with CSS 
      diagnosed according to ACR 1990 criteria, 30 healthy controls (HC) and 57 disease 
      controls (28 asthma, 20 small vessel vasculitis, 9 hypereosinophilic syndrome) 
      were studied. Clinical data were collected and serum levels of eotaxin-1, -2 and 
      -3 were determined by ELISA. Further, immunohistochemistry was applied to 
      identify eotaxin-3 expression in tissue biopsies from patients with CSS. RESULTS: 
      In contrast to eotaxin-1 and -2, eotaxin-3 was highly elevated in serum samples 
      of active CSS patients and correlated highly significantly with eosinophil 
      counts, total immunoglobulin E (IgE) levels and acute-phase parameters. Moreover, 
      eotaxin-3 was not elevated in other eosinophilic and vasculitic diseases. 
      Immunohistochemical analysis revealed strong expression of eotaxin-3 in 
      endothelial and inflammatory cells in affected tissues of active CSS patients. 
      CONCLUSIONS: This study reveals the specific association of elevated eotaxin-3 
      expression with high disease activity and eosinophilia in CSS patients. Eotaxin-3 
      might thus be a pathogenic player, biomarker and potential therapeutic target in 
      CSS.
FAU - Polzer, K
AU  - Polzer K
AD  - Department of Internal Medicine 3 and Institute for Clinical Immunology, 
      University of Erlangen-Nuremberg, Krankenhausstrasse 12, 91054 Erlangen, Germany.
FAU - Karonitsch, T
AU  - Karonitsch T
FAU - Neumann, T
AU  - Neumann T
FAU - Eger, G
AU  - Eger G
FAU - Haberler, C
AU  - Haberler C
FAU - Soleiman, A
AU  - Soleiman A
FAU - Hellmich, B
AU  - Hellmich B
FAU - Csernok, E
AU  - Csernok E
FAU - Distler, J
AU  - Distler J
FAU - Manger, B
AU  - Manger B
FAU - Redlich, K
AU  - Redlich K
FAU - Schett, G
AU  - Schett G
FAU - Zwerina, J
AU  - Zwerina J
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20080408
PL  - England
TA  - Rheumatology (Oxford)
JT  - Rheumatology (Oxford, England)
JID - 100883501
RN  - 0 (Biomarkers)
RN  - 0 (CCL11 protein, human)
RN  - 0 (CCL24 protein, human)
RN  - 0 (CCL26 protein, human)
RN  - 0 (Chemokine CCL11)
RN  - 0 (Chemokine CCL24)
RN  - 0 (Chemokine CCL26)
RN  - 0 (Chemokines, CC)
SB  - IM
MH  - Adult
MH  - Biomarkers/blood/metabolism
MH  - Biopsy
MH  - Chemokine CCL11/blood
MH  - Chemokine CCL24/blood
MH  - Chemokine CCL26
MH  - Chemokines, CC/*blood/metabolism
MH  - Churg-Strauss Syndrome/*blood/metabolism/pathology
MH  - Eosinophilia/blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Vasculitis/blood
EDAT- 2008/04/10 09:00
MHDA- 2008/06/27 09:00
CRDT- 2008/04/10 09:00
PHST- 2008/04/10 09:00 [pubmed]
PHST- 2008/06/27 09:00 [medline]
PHST- 2008/04/10 09:00 [entrez]
AID - ken033 [pii]
AID - 10.1093/rheumatology/ken033 [doi]
PST - ppublish
SO  - Rheumatology (Oxford). 2008 Jun;47(6):804-8. doi: 10.1093/rheumatology/ken033. 
      Epub 2008 Apr 8.